Michael R. Page, PharmD, RPh

Chronic lung disease may increase the risk of developing lung cancer, independently of tobacco use and other known risk factors.

A patient's lifetime risk of developing type 2 diabetes currently stands at 40%, with an even higher risk for some ethnic groups.

Investigators in Europe have confirmed the effectiveness of prostate-specific antigen screening in reducing the risk of cancer-related mortality and in detecting a larger share of prostate cancer cases.

Nearly 1 in 6 lupus patients hospitalized in the United States are readmitted within 30 days.

Following favorable results of the ASPIRE clinical trial, Amgen acquired Onyx Pharmaceuticals for an estimated $9.7 billion.

A phase 2 trial reported 100% 3-year overall survival rates with frontline therapy consisting of lenalidomide, bortezomib, and dexamethasone in younger patients with multiple myeloma.

Screening of newborn children for hepatitis C and new, more effective hepatitis C treatments may virtually eliminate the disease in the United States by 2036.

In a study that has the potential to change public health recommendations for breast cancer screening, researchers have validated the value of mammography in older women.

Learn what the latest guidelines from the American Academy of Pediatrics recommend for meningococcal vaccination among children, adolescents, and young adults.

Children who grow up in stressful settings are at higher risk of developmental problems that may later manifest as chronic disease. Fortunately, support programs may help reduce stress and improve outcomes.

Increasingly, sharing of information online through social media has made blinding of placebo groups in clinical trials virtually impossible. In some disease states, particularly multiple sclerosis, virtual placebo groups may offer a solution.

Researchers in Taiwan have found an increased risk for head and neck cancers among patients with diabetes mellitus.

Male latex condoms are still the best strategy for reducing the spread of HIV infection.

Researchers in Taiwan have found an increase in the risk for head and neck cancers among patients with diabetes mellitus (DM) equivalent to approximately 2.6 additional cases per 10,000 person-years in patients with DM versus patients without DM.

Through a metaanalysis, researchers in Australia have confirmed a slight antihypertensive effect with use of probiotics that was consistent through 9 studies.

Methotrexate, a traditional disease-modifying antirheumatic drug, may enhance the likelihood of therapeutic persistence with novel biologic agents.

A study indicates that BPA-induced cancers in female rats may lead to tumors with evidence of both genetic and epigenetic changes.

Researchers at the Dana-Farber Cancer Institute and Brigham and Women's Hospital have tested a nanomedicine technology in mice formulated to precisely target myeloma cancer cells with a novel bortezomib delivery system.

Researchers in the United Kingdom have identified a blood test for circulating free DNA that may help physicians predict whether or not a patient with breast cancer is likely to respond to an initial round of chemotherapy, enabling earlier initiation of alternate treatments.

New hypertension guidelines from the American Society of Hypertension and the International Society of Hypertension differ from the JNC 8 guidelines on several key points.

According to a retrospective study and a registry analysis, statin therapy may reduce the rate of local breast cancer recurrence in certain types of breast cancer.

LBH589, when used in combination with bortezomib and dexamethasone, improved progression-free survival among relapsed and refractory patients with multiple myeloma.

A genetic test in development by Micromedic may help identify patients who are likely to develop bisphosphonate-associated osteonecrosis of the jaw.

Results from 2 large, long-term clinical trials show benefits of extended-duration treatment with tamoxifen, resulting in an update to treatment guidelines.

Patients with HIV who smoke may be at even greater risk of developing smoking-related cancers.

Opexa Therapeutics is initiating a phase IIb trial of a novel therapy that targets T-cells in patients with secondary progressive multiple sclerosis.

Using Captisol technology, scientists have developed a more stable formulation of melphalan that may facilitate higher-intensity regimens in patients with multiple myeloma undergoing autologous stem cell transplant procedures.

According to a recent study, one-fifth of those aged 60 or older who were candidates for pharmacologic therapy under JNC 7 would rely on lifestyle blood pressure control under JNC 8.

A variety of treatments to counteract the bone-wasting effects of multiple myeloma are in development.